Campbell Newman Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Campbell Newman Asset Management's CPRX Position: Q2 2026 in Review

Campbell Newman Asset Management increased its Catalyst Pharmaceutical (CPRX) stake by 4.6% in Q2 2026, buying an estimated $124K and bringing the position to 96,690 shares worth $3.04M. The position accounts for 0.23% of the portfolio, ranked #49.

Campbell Newman Asset Management first reported a position in CPRX in Q1 2024 and has held it in 10 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

• Campbell Newman Asset Management held 96,690 shares of Catalyst Pharmaceutical worth $3.04M as of Q2 2026.
• Campbell Newman Asset Management bought 4,214 Catalyst Pharmaceutical shares in Q2 2026, an estimated $124K.
• Catalyst Pharmaceutical made up 0.23% of Campbell Newman Asset Management's portfolio in Q2 2026, its #49 holding.
• Campbell Newman Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
• 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Campbell Newman Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.